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Abstract
Background: To compare the efficacy of sorafenib and sunitinib with regard to overall survival (OS) and progression
free survival (PFS) in Chinese patients with metastatic renal cell carcinoma (mRCC).
Methods: A multicenter, retrospective study was performed to elucidate the relationship between clinical variables
and prognosis comparing sorafenib and sunitinib as first-line treatment agents in Chinese patients with mRCC.
Between September 2006 and December 2014, 845 patients received either sorafenib (400 mg bid; n = 483) or
sunitinib (50 mg q.d; n = 362). The primary end point was OS and PFS.
Results: The percentage of patients with low and moderate risk according to Memorial Sloan-Kettering Cancer Centre
(MSKCC) score was significantly higher in sunitinib group, and that with high risk was significantly higher in sorafenib
group (15.1 vs. 5.2%; p < 0.001). Median OS was similar in sorafenib and sunitinib group (24 vs. 24 months; p = 0.298).
Sorafenib group exhibited higher mPFS compared to sunitinib group (11.1 vs. 10.0 months; p = 0.028). Treatment
(sorafenib vs sunitinib), pathology, Eastern Cooperative Oncology Group (ECOG) performance status, MSKCC scores,
Heng’s criteria of risk, and number of metastases were identified as significant predictors for OS and along with liver
metastasis for PFS. Clinical outcomes in terms of mOS was significantly better with sorafenib in patients ≥65 years of
age (p = .041), ECOG 0 (p = 0.0001), and median MSKCC risk score (p = 0.008).
Conclusions: Sorafenib and sunitinib are both effective in treating mRCC. However, sorafenib might be more effective
in elderly patients (≥65 years) and in patients with an ECOG status of 0, classified under MSKCC moderate risk.
Keywords: Metastatic renal cell carcinoma, Sorafenib, Sunitinib, Prognosis, Survival
* Correspondence: dwyeli@163.com; guoj307@126.com
Hai-Liang Zhang and Xi-Nan Sheng are co-first authors.
†Equal contributors
1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai
200032, People’s Republic of China
3Key Laboratory of Carcinogenesis and Translational Research (Ministry of
Education/Beijing), Department of Renal Cancer and Melanoma, Peking
University Cancer Hospital & Institute, Beijing, People’s Republic of China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. BMC Cancer  (2017) 17:16 
DOI 10.1186/s12885-016-3016-4
Background
It is evident that ~30% of renal cell carcinoma (RCC) pa-
tients have overt metastases, defined as metastatic RCC
(mRCC) [1] with a very poor average 5-year survival rate
(only 10–12%) [2]. The growing evidence on the associa-
tions of molecular mechanisms with mRCC and also the
abstinence of cytokine-based therapies due to high tox-
icity profile [3–5] has rationalized several randomized
clinical trials on molecular targeted therapies such as so-
rafenib [6], bevacizumab [4], temsirolimus [7], sunitinib
[8], pazopanib [9], everolimus [10], and axitinib [11] as
first- and second-line treatment, which were found to be
efficacious and safer than conventional immunotherapy.
The availability of these targeted therapies has resulted
in prolonged overall survival (OS) to approximately
2 years, thereby emerging as the standard of care in the
management of mRCC. However, efficacy of drugs used
in cancer chemotherapy is often associated with distinct-
ive challenges due to infrequent occurrence of measur-
able disease, prolonged natural history of disease, diverse
clinical characteristics and greater likelihood of contrary
outcomes when treating elderly patients with more ag-
gressive treatments [12, 13]. These challenges also influ-
ence regular, as well as accelerated regulatory approvals
of drugs, which require extensive evidence of efficacy de-
rived from clinical trials in addition to accommodating
integral characteristics of disease and patient population
[14]. Also, first-line therapies should be strategically
chosen in order to devoid the need of sequential therapy
with second-line therapies. For this purpose, comparing
the efficacy of drugs may offer substantial evidence and
guidance on the optimal use of targeted therapies. When
evaluated as first-line treatment, axitinib demonstrated
clinical efficacy and safety, but no significant progression
free survival (PFS) benefit over sorafenib in a Phase III
randomized comparison [15]. Further, sunitinib had simi-
lar efficacy as pazopanib in a non-inferiority trial [16].
Moreover, in case of sunitinib failure in advanced RCC,
everolimus and axitinib appear to provide second-line PFS
benefits [17]. On the other hand, recent Phase III Investi-
gating Torisel as Second-Line Therapy (INTORSECT)
trial reported no significant benefit of either temsirolimus
or sorafenib as second-line treatment after sunitinib
failure [7], though, temsirolimus demonstrated clinical
efficacy as first-line therapy in poor risk patients [18].
Although sorafenib is a comparator agent in several
clinical trials and often used as a second-line therapy,
Chinese patients have been more responsive to sorafenib
than western patients, hence, both sunitinib and sorafenib
are widely recommended first-line therapies in China [19].
However, studies directly comparing efficacy of the two
therapies in first-line settings which may guide the clinical
decisions of mRCC treatment in Asian patients are lim-
ited. Although, a Korean study has reported comparable
efficacy of the 2 drugs in mRCC patients, the findings
were limited due to small patient population and a single
centric retrospective design, warranting additional in-
vestigation [20]. Hence this study aims to retrospectively
elucidate the relationship between clinical variables and
disease prognosis by comparing sorafenib versus sunitinib




Records of patients with mRCC were maintained at the
Beijing Cancer Hospital, Fudan University Shanghai Can-
cer Centre and the Peking University First Hospital. Be-
tween September 2006 and December 2014, the patient
records were retrospectively reviewed and computed
tomography (CT) scans were independently reviewed
by a senior radiologist, blinded to a treatment arm.
Patients between 18 and 84 years of age; histological
confirmation of advanced/mRCC; unsuitable for cytokine
therapy; no prior systemic therapy; Eastern Cooperative
Oncology Group performance status (ECOG PS) 0 to 3; 1
or more measurable lesions by CT or magnetic resonance
imaging (MRI) according to Response Evaluation Criteria
in Solid Tumors (RECIST 1.0); favorable or intermediate
Memorial Sloan Kettering Cancer Centre (MSKCC) risk
score; adequate bone marrow, liver, and renal function
and willing to undergo first-line targeted therapy with so-
rafenib or sunitinib are included. Patients were excluded if
they had unstable or severe cardiac disease; active, clinic-
ally serious infection or symptomatic metastatic brain
tumor and with ECOG PS 4 and 5. Ethical approval was
obtained from institutional ethics committee of Beijing
Cancer Hospital, Fudan University Shanghai Cancer
Centre and the Peking University First Hospital, and
the protocol conformed to the principles of declaration
of Helsinki, its subsequent revisions. Patient signed in-
formed consent was obtained.
Treatment
All the patients received first-line treatment with either
sorafenib or sunitinib as monotherapy. Sorafenib was ad-
ministered at a dose of 400 mg twice daily and sunitinib
at a dose of 50 mg q.d. Dose reduction or temporary
suspension was carried out if grade 3–4 adverse event
(AE) was reported according to the local prescribing in-
formation (PI). However, sorafenib dosage was increased
to 600 mg twice daily and subsequently to 800 mg twice
daily in some patients with disease progression.
Outcomes and assessments
The primary endpoint was OS (calculated from the date
of first dose of sorafenib to the date of death or last
follow-up) and PFS (time from first administration of
Zhang et al. BMC Cancer  (2017) 17:16 Page 2 of 10
sorafenib to the first documentation of disease progres-
sion or death from any cause). The effect of important
prognostic factors such as age, gender, MSKCC score,
ECOG performance and number of metastatic tumors
on PFS and OS were evaluated.
Statistical analysis
Continuous variables such as PFS and OS were reported
as medians and interquartile ranges, and categorical data
such as age, gender, previous nephrectomy or systemic
therapy were presented as proportions. The follow-up
duration was calculated using reversed Kaplan-Meier
method. The Shapiro-Wilk test was used to evaluate the
data for normality distribution. OS and PFS were esti-
mated using the Kaplan-Meier method with Rothman’s
95% CI and compared across groups using the log-rank
test. The Cox proportional hazards model was used to
evaluate the prognostic value of investigated parameters.
All p values were two-sided and were considered signifi-
cant if <.05. The concordance index and the proportion
of 2 explained variance (R) was computed to assess the
prediction performance for survival (PFS and OS). The
statistical analysis of the collected data was performed
using SPSS software version 19.
Results
Patients and baseline demographics
The data of 845 patients with mRCC enrolled between
September 2006 and December 2014 were analyzed.
Baseline demographics and clinical characteristics of the
study population are presented in Table 1. Of the 845
patients, 483 were treated with sorafenib and 362 were
treated with sunitinib. Majority of patients were ≤65 years
of age and were predominantly men in both the treatment
groups (age ≤65 years: 77.2% vs. 85.4%; males: 73.1% vs.
76.2% in sorafenib and sunitinib group, respectively). Ap-
proximately, 48% of the patients in the sorafenib group
and 66% in the Sunitinib group had an ECOG perform-
ance status of 0, and majority of patients in both the
groups were at moderate risk according to the MSKCC
score (49.1% vs. 53%) and Heng’s score (47% vs 51.7%).
There were significantly more number of patients with
non-clear cell-type RCC in the sorafenib group (15.5% vs.
8.6%; p = 0.002). However, the number of patients at low
and moderate risk according to MSKCC score were sig-
nificantly more in the sunitinib group and the number of
patients at high risk according to MSKCC score were sig-
nificantly more in the sorafenib group (15.1% vs. 5.2%; p <
0.001). No significant differences between the 2 treatment
groups were observed for parameters such as gender,
number of metastases, bone metastasis and simple bone
metastasis.
Endpoint analysis
Survival data are presented in terms of OS and PFS. Me-
dian OS (mOS) and PFS (mPFS) for both the treatment
groups are shown in Fig. 1. Median OS (months) for the
sorafenib and sunitinib groups was found to be similar
(24.0 vs. 24.0; p = 0.298). Overall, the sorafenib group ex-
hibited higher mPFS (months) when compared to suniti-
nib group (11.1 vs. 10.0; p = 0.028). Overall response rate
(CR + PR) of sorafenib treatment was 16.77% (82/483)
was lower than sunitinib treatment 20.99% (76/362). Dis-
ease control rate (CR + PR + SD) was similar in 2 groups
88.61% (428/483) vs 88.39% (320/362). Disease progression
was seen in 11.4% patients in sorafenib group and 11.6% in
sunitinib. Only 27.3% in the sorafenib group and 22.4% in
the sunitinib group had dose escalation which was consid-
ered as second line treatment.
Predictor analysis
Univariate analysis of 12 key including demographic and
clinical characteristics identified pathology of RCC (clear
cell and non-clear cell type), ECOG performance status,
MSKCC score for risk, Heng’s criteria for risk, number
of metastasis, simple lung metastasis, bone metastasis
and liver metastasis as significant predictors for OS (p =
0.000) and PFS (p = 0.000). Additionally, simple bone
metastasis was also identified as a significant predictor
of PFS (p = 0.016). Data from univariate analysis of OS
and PFS predictors are detailed in Table 2. However,
multivariate analysis identified variables such as treatment
(sorafenib vs. sunitinib), pathology, ECOG performance
status, MSKCC scores, Heng’s criteria of risk and number
of metastases as significant predictors for OS (Fig. 2). For
PFS, liver metastasis along with other variables reported
for OS were identified as significant predictors (Table 3,
Fig. 3). Clinical outcomes in terms of mOS seemed to be
significantly better with sorafenib in patients older than
65 years (p = 0.041), ECOG of 0 (p < 0.001) and median
MSKCC risk score (p = 0.008).
Further, multivariate analysis revealed significant associ-
ation between OS and several predictors such as sorafenib
treatment (HR 1.3, 95% CI 1.096, 1.542; p= 0.003), Clear cell
type RCC (HR 1.49, 95% CI 1.167, 1.922; p= 0.002), ECOG
grade 3 (HR 1.22, 95% CI 1.082, 1.385; p= 0.001), high grade
MSKCC 3 (HR 1.36, 95% CI 1.086, 1.703; p= 0.007), Heng
risk (HR 1.53, 95% CI 1.244, 1.889; p < 0.0001), presence of
liver (HR 1.40, 95% CI 1.067, 1.846; p= 0.001), and lymph
node metastases (HR 1.22, 95% CI 1.082, 1.385; p= 0.001).
Other prognostic factors such as gender, age, second line
treatment, lung and bone metastasis and previous nephrec-
tomy showed no significant association with OS (Table 4).
Discussion
Sorafenib and sunitinib have been used for mRCC in
China since 2007. Since then several studies have tried
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to elucidate the efficacy of the novel treatments. OS is a
reliable endpoint for assessing the efficacy of mRCC with
targeted therapy [21]. Although, these new therapies
have improved the OS and PFS of patients with mRCC,
gradual development of drug resistance may often lead
to switching one therapy to other, resulting in sequential
Table 1 Baseline characteristics of the study population
Clinical variable Sorafenib, n (%) Sunitinib, n (%) P
Age (years) <65 373 (77.2) 309 (85.4) 0.004
≥65 110 (22.8) 53 (14.6)
Gender Male 353 (73.1) 276 (76.2) 0.302
Female 130 (26.9) 86 (23.8)
Pathology Clear cell type 408 (84.5) 331 (91.4) 0.002
Non-clear cell type 75 (15.5) 31 (8.6)
ECOG 0 230 (47.6) 238 (65.7) <0.001
1 188 (38.9) 94 (26.0)
2 58 (12.0) 29 (8.0)
3 7 (1.4) 1 (0.3)
Previous nephrectomy Yes 376 (77.8) 298 (82.3) 0.120
No 107 (22.2) 64 (17.7)
MSKCC Low risk 173 (35.8) 151 (41.7) <0.001
Moderate risk 237 (49.1) 192 (53.0)
High risk 73 (15.1) 19 (5.2)
Heng’s criteria Low risk 183 (37.9) 144 (39.8) 0.016
Moderate risk 227 (47.0) 187 (51.7)
High risk 73 (15.1) 31 (8.6)
Number of metastatic organs 1 207 (42.9) 174 (48.1) 0.129
2 182 (37.7) 109 (30.1)
3 75 (15.5) 66 (18.2)
4 19 (3.9) 13 (3.6)
Lung metastasis No 174 (36.0) 106 (29.3) 0.046
Yes 309 (64.0) 256 (70.7)
Simple lung metastasis No 380 (78.7) 251 (69.3) 0.002
Yes 103 (21.3) 111 (30.7)
Bone metastasis No 319 (66.0) 254 (70.2) 0.207
Yes 164 (34.0) 108 (29.8)
Simple bone metastasis No 445 (92.1) 341 (94.2) 0.276
Yes 38 (7.9) 21 (5.8)
Liver metastasis No 421 (87.2) 335 (92.5) 0.013
Yes 62 (12.8) 27 (7.5)
Lymph node metastasis No 323 (66.9) 248 (68.5) 0.656
Yes 260 (33.1) 114 (31.5)
RECIST response CR 5 (1.0) 4 (1.1)
PR 77 (15.9) 72 (19.9)
SD 346 (71.6) 244 (67.4)
PD 55 (11.4) 42 (11.6) 0.110
Second line treatment Yes 132 (27.3) 81 (22.4)
No 351 (72.7) 281 (77.6)
ECOG eastern cooperative oncology group, MSKCC memorial sloan-kettering cancer centre, OS overall survival, PFS progression-free survival
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therapy. Filson et al. reported that patients on first-line
sorafenib therapy have high probability of proceeding to
second-line therapy with sunitinib [22]. This clearly indi-
cates the difference between the efficacies of the two
drugs. However, a Korean study revealed comparable ef-
ficacy outcomes of sorafenib and sunitinib when used as
monotherapy in first-line settings [20]. In support to the
Korean study, more Asian studies are warranted to elu-
cidate the efficacies of these therapies to inform the
choice of first-line therapies.
Evidence-based studies suggest both first- and second-
line efficacy of sorafenib. Earlier trials have shown com-
parable efficacy of sorafenib with interferon alpha-2a
(PFS: 5.7 vs 5.6 months respectively), were the sorafenib
treatment was well tolerated by the patients [23]. Also,
in the INTORSECT trial, sorafenib had significantly lon-
ger OS compared to temsirolimus in first line therapy
[7]. Further, a non-randomized open access trial demon-
strated that sorafenib provides similar benefits in both
first- and second-line setting [15]. The recent findings
from an Italian study further confirmed that sorafenib
prolonged PFS and OS in both first- and second-line
routine community practice setting [24]. On the other
hand, sunitinib also has established efficacy in previous
phase 3 trials. Further, the efficacy of sunitinib was found
to be superior to IFN-alpha but comparable to pazopanib
across the trails, however severe grade 3 or 4 adverse ef-
fects were the limitations [8, 25].
Though efficacies of both the drugs in first-line setting
are well described in retrospective literature, head-to-
head comparison of real world clinical outcomes in pa-
tients are more heterogeneous than those trailed under
controlled conditions, were patients with independent
prognostic risk factors such as elderly, ECOG perform-
ance status and MSKCC Moderate risk groups were ex-
cluded. Considering the limitation of the clinical trials,
expanded-access studies were conducted in America
[26] and Europe [27] on sorafenib and one study on su-
nitinib [28], which were close to the real world scenario.
Further, patient age may be a pivotal prognostic factor as
elderly patients tend to have lower ECOG performance
status than younger patients [29]. Hence, head-to-head
comparisons are needed to inform the choice of treat-
ment for such selected patients.
Our previous report documented higher clinical benefit
rate in sorafenib treated patients than sunitinib treated pa-
tients (94.67% vs 84.33%) [30]. In extension to this, the
present retrospective review reported similar effectiveness
of sorafenib and sunitinib in treating Chinese patients
with mRCC, however, sorafenib therapy was more effect-
ive in elderly patients (≥65 years) and in patients with an
normal performance status who were classified under
MSKCC moderate risk category. A sub analysis of elderly
patients in a phase 3 trial revealed a significant PFS ad-
vantage of sorafenib regardless of age [19]. In contrast,
expanded-access studies on the clinical outcomes of su-
nitinib reproduced consistent efficacy and safety outcomes
with previous results, and the outcomes were fairly similar
in both elderly and younger populations but with sig-
nificantly more common adverse effects seen in older
population. However the clinical benefits of OS and
PFS were inferior compared with placebo [28]. In line
with our findings, a Swedish register-based demonstrated
no difference between sorafenib and sunitinib in the dur-
ation of treatment or time to death when used as first-line
therapy, however, the impact of the duration of first-line
treatment differed in sequential therapy, concluding soraf-
enib first line treatment as a favorable choice in mRCC
[31]. Furthermore, comparison of the present mOS find-
ings with sorafenib therapy with other Asian studies dem-
onstrated mixed results, where the mOS was consistent
with a Chinese study12 conducted by Yu et al. [32], but
were lower than the other Chinese [33, 34] and Korean
studies [20]. However, higher mPFS with sorafenib over
sunitinib was demonstrated in this study compared to pre-
vious Chinese [32], Korean [20, 35] and Italian [24] stud-
ies. The discrepancy may be related to diversity of patient
populations enrolled in each study differing in many as-
pects related to prognosis and ethnicity. Furthermore,
studies suggest that compared with Western patients,
Fig. 1 Survival data of first-line targeted therapy for advanced renal carcinoma
Zhang et al. BMC Cancer  (2017) 17:16 Page 5 of 10
Chinese patients respond better to sorafenib as first-line
targeted therapy [36, 37] Also, the results from TIVO-1
trial suggested that sorafenib as a first-line mRCC therapy
yielded PFS of 9.1 month [38], which was lesser than the
findings from the present study (PFS 11.1 months). Hence,
the present study findings further support the previous
Table 2 Univariate analysis of predictors for OS and PFS
Clinical variable mOS (months) Log Rank test, P mPFS (months) Log Rank test, P
Gender Male 24.0 0.413 11.0 0.131
Female 23.0 10.0
Age <65 years 24.0 0.714 10.6 0.435
≥65 years 24.0 11.0
Pathology Clear cell type 25.5 <0.001 11.3 <0.001
Non-clear cell type 14.0 7.0




Previous nephrectomy Yes 26.7 <0.001 11.6 <0.001
No 14.0 7.0
MSKCC Low risk 39.0 <0.001 15.0 <0.001
Moderate risk 22.0 9.5
High risk 9.3 5.2
HENG Low risk 39.0 <0.001 15.0 <0.001
Moderate risk 22.0 9.4
High risk 10.3 5.8




Lung metastasis No 23.0 0.362 10.0 0.429
Yes 24.0 11.0
Simple lung metastasis No 21.4 <0.001 9.3 <0.001
Yes 32.4 15.0
Bone metastasis No 26.0 <0.001 12.0 0.001
Yes 20.4 9.0
Simple bone metastasis No 24.0 0.182 10.5 0.016
Yes 24.0 12.0
Liver metastasis No 25.0 <0.001 11.3 <0.001
Yes 15.0 6.0
Lymph node metastasis No 27.5 <0.001 12.0 <0.001
Yes 18.0 9.0




Second line treatment Yes 30.0 0.024 10.9 0.363
No 22.0 10.5
ECOG eastern cooperative oncology group, MSKCC memorial sloan-kettering cancer centre, OS overall survival, PFS progression-free survival
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findings with regards to superior efficacy of sorafenib in
Chinese patients with mRCC.
Furthermore, multivariate regression analysis revealed
treatment (Sorafenib vs. Sunitinib), pathology, ECOG
performance status, MSKCC scores, HENG criteria of
risk, and number of metastases as significant predictors
for OS which is in line with the previous studies con-
ducted by Motzar et al., which demonstrated ethnicity,
ECOG status, bone metastasis and old age as predictors
for OS and PFS in first-line therapy with sunitinib [39].
The findings are also consistent with the findings of
Yang et al. who reported MSKCC status as prognostic
factor for OS and PFS when treated with sunitinib [40].
Overall, our study findings support the findings of the
Swedish and Italian studies, demonstrating comparable
efficacy of sorafenib over sunitinib, but a more favorable
sorafenib therapy in elderly and moderate risk mRCC
patients.
Our study has several limitations. The retrospective
design of the study comes as an inherent limitation;
however, relatively large sample size compared to previ-
ous retrospective studies may power the study. The
Fig. 2 Multivariate analysis of predictors of OS. ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan-Kettering Cancer Centre; OS,
overall survival
Table 3 Multivariate analysis of predictors for PFS
Variables P HR 95.0% CI
Lower Upper
Drug Sorafenib vs Sunitinib <0.001 1.420 1.211 1.664
Gender Male vs Female 0.414 1.074 0.906 1.273
Age <65 vs > =65 0.194 0.879 0.723 1.068
Pathology Clear cell vs Non clear cell 0.024 1.312 1.037 1.660
ECOG 0 vs 1 vs 2 vs 3 <0.001 1.245 1.105 1.402
Previous nephrectomy No vs Yes 0.500 0.931 0.755 1.147
MSKCC Low vs median vs High 0.043 1.253 1.007 1.558
HENG Low vs median vs High <0.001 1.458 1.198 1.774
Number of metastatic organs 1 vs 2 vs 3 vs 4 0.679 1.033 0.886 1.204
Lung metastasis Yes vs No 0.175 1.173 0.931 1.478
Single lung metastasis No vs Yes 0.188 0.834 0.637 1.092
Bone metastasis Yes vs No 0.108 1.193 0.962 1.481
Single bone metastasis No vs Yes 0.085 0.703 0.470 1.050
Liver metastasis Yes vs No <0.001 1.645 1.263 2.142
Lymph node metastasis Yes vs No 0.023 1.250 1.031 1.516
Second line treatment No vs Yes <0.001 1.398 1.184 1.651
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favorable outcomes of sorafenib demonstrated in this
study may create a conflict in the belief of the clinicians
who believe sunitinib as a better first-line option. Fur-
ther, mOS was chosen as an endpoint and hence, the
survival probability at a later time point after treatment
initiation could not be established, hence, warranting
further long term comparative efficacy studies.
Conclusion
The present study suggests that sorafenib and sunitinib
are both effective as first-line therapeutic agents in treat-
ing Chinese patients with mRCC. Sorafenib is effective in
elderly patients (≥65 years) and in patients with an ECOG
status of 0, classified under MSKCC moderate risk. In
addition, multivariate analysis suggests that variables such
Table 4 Multivariate analysis of predictors for OS
Variables P HR 95.0% CI
Lower Upper
Drug Sorafenib vs Sunitinib 0.005 1.283 1.080 1.524
Gender Male vs Female 0.984 1.002 0.834 1.204
Age <65 vs > =65 0.784 0.971 0.789 1.196
Pathology Clear cell vs Non clear cell 0.002 1.498 1.167 1.924
ECOG 0 vs 1 vs 2 vs 3 0.002 1.219 1.078 1.379
Previous nephrectomy No vs Yes 0.229 0.872 0.697 1.090
MSKCC Low vs median vs High 0.008 1.354 1.081 1.694
HENG Low vs median vs High <0.0001 1.526 1.239 1.880
Number of metastatic organs 1 vs 2 vs 3 vs 4 0.084 1.149 0.982 1.345
Lung metastasis Yes vs No 0.045 1.285 1.005 1.642
Single lung metastasis No vs Yes 0.204 0.831 0.624 1.106
Bone metastasis Yes vs No 0.985 1.002 0.798 1.258
Single bone metastasis No vs Yes 0.897 0.972 0.634 1.492
Liver metastasis Yes vs No 0.017 1.398 1.062 1.840
Lymph node metastasis Yes vs No 0.014 1.289 1.054 1.577
Second line treatment No vs Yes 0.198 0.886 0.737 1.065
Fig. 3 Multivariate analysis of predictors of PFS. ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan-Kettering Cancer Centre; OS,
overall survival
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as treatment (sorafenib vs sunitinib), pathology, ECOG
performance status, MSKCC scores, Heng’s criteria of risk
and number of metastases are significant prognostic
factors for OS and PFS.
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